GlassScriptPhysician profile
Sarah E Ducharme
NPI 1609853951
$10,638.55
in general payments reported to CMS, 2019-2025
29 companies · $2,538 in 2025
The $2,538 reported for 2025 was more than what 84% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $1,669 · 2021: $1,549 · 2022: $431 · 2023: $644 · 2024: $3,230 · 2025: $2,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Travel and Lodging: $1,792 · Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Travel and Lodging | $1,791.70 |
| Food and Beverage | $1,619.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merakris Therapeutics, INC. | $3,000.00 | 2024 | |
| Smith+Nephew, INC. | $2,700.43 | 2019-2025 | Pico, Collagenase Santyl, Grafix |
| Musculoskeletal Transplant Foundation INC. | $2,683.26 | 2020-2023 | |
| Integra Lifesciences Corporation | $245.53 | 2019-2025 | Gentrix |
| Amgen INC. | $230.92 | 2019-2021 | |
| Misonix INC | $207.97 | 2020-2021 | |
| Abbvie INC. | $201.31 | 2021-2024 | Dalvance |
| Innocoll Pharmaceuticals Limited | $174.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.20 | 2020-2021 | |
| Acacia Pharma INC | $162.52 | 2021 | |
| Solventum Corporation | $113.73 | 2024-2025 | Silvercel, V.A.C. Dermatac, Activ.A.C. |
| Organogenesis INC. | $109.54 | 2020-2023 | Puraply |
| Kerecis Limited | $94.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.20 | 2019 | |
| Osiris Therapeutics INC. | $57.64 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $53.16 | 2021 | |
| Myovant Sciences INC. | $50.04 | 2021 | |
| Merck Sharp & Dohme LLC | $47.98 | 2021 | |
| Biowound Solutions, INC. | $46.17 | 2025 | Bio-Connekt |
| Tactile Systems Technology INC | $42.56 | 2019-2021 | |
| Tela Bio, INC. | $26.54 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Myriad Genetic Laboratories, INC. | $26.25 | 2021 | |
| Baxter Healthcare | $21.06 | 2020 | |
| Molnlycke Health Care US, LLC | $19.14 | 2021 | |
| Bioventus LLC | $17.64 | 2022 | |
| Averitas Pharma INC. | $17.21 | 2025 | Qutenza |
| Medela LLC | $15.00 | 2021 | |
| Avanos Medical | $10.84 | 2019 | |
| Advanced Oxygen Therapy INC. | $7.76 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Ducharme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.